The horror arrived in a fifteen dollar vial. In the backstreets of Mumbai and the glistening labs of Shanghai, the velvet rope of the metabolic elite has been cut. For years, the fifteen hundred dollar a month receipt for semaglutide was the ultimate quiet luxury. It was a sign you were part of the 'Wegovy set'. You were thin because you were wealthy. Now, as patents expire, the world's most desired molecule is being dumped into the bargain bin of the Global South. Over fifty generic brands are flooding the market. Novo Nordisk is panicking. They are launching 'Wegovy HD'—a higher-dose, premium variant designed to keep the riff-raff at bay. It is a metabolic arms race. In Mayfair, the mood is funereal. One socialite was heard weeping into her green juice at the thought of the middle class sharing her jawline. The FDA has approved the new high-dose shot just in time for the Hamptons season. It offers twenty-one percent weight loss. That is a numerical flex that the cheap versions simply cannot match. This is no longer about health. It is about the distance between the top of the ladder and the bottom. The generic flood threatens to make us all equal. And in the world of The Hedonist, equality is the ultimate aesthetic crime. We are entering the era of 'Wegovy HD' versus the 'Ozempic masses'. Choose your side, but choose your dose carefully.